Shots: The study involves assessing efficacy and safety of CT-P10 vs Rituxan (rituximab) in 140 patients in ratio (1:1) with AFL for a duration of two years P-III study results: @ 2 Year OS (93.2% vs 95.3%); PFS (75.2% vs 73.5%); relapse or disease progression (19.4% vs 21.3%); well tolerated and safe, Presented at ASH […]Read More
